HDAC9 and Alzheimer disease: The memories consolidated by HDACi-treated transgenic mice remained stable over a two-week period, suggesting that targeted inhibition of class I HDAC isoforms is a promising therapeutic approach for cognitive deficits in early-stage AD [70].